These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
741 related articles for article (PubMed ID: 16754936)
1. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936 [TBL] [Abstract][Full Text] [Related]
2. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677 [TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660 [TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of bortezomib in relapsed, refractory myeloma. Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635 [TBL] [Abstract][Full Text] [Related]
5. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066 [TBL] [Abstract][Full Text] [Related]
6. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients. Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392 [TBL] [Abstract][Full Text] [Related]
9. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291 [TBL] [Abstract][Full Text] [Related]
11. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E; J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495 [TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068 [TBL] [Abstract][Full Text] [Related]
16. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602 [TBL] [Abstract][Full Text] [Related]
17. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004 [TBL] [Abstract][Full Text] [Related]
19. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114 [TBL] [Abstract][Full Text] [Related]
20. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]